Stock analysts at BMO Capital Markets started coverage on shares of ARMO Biosciences (NASDAQ:ARMO) in a research note issued to investors on Tuesday, February 20th, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $75.00 price target on the stock. BMO Capital Markets’ target price would suggest a potential upside of 62.97% from the company’s current price.
Separately, Jefferies Group started coverage on ARMO Biosciences in a report on Tuesday, February 20th. They set a “buy” rating and a $61.00 target price on the stock.
Shares of ARMO Biosciences (NASDAQ:ARMO) traded down $3.74 during trading hours on Tuesday, hitting $46.02. The company had a trading volume of 175,792 shares, compared to its average volume of 229,197. ARMO Biosciences has a twelve month low of $27.00 and a twelve month high of $57.19.
ARMO Biosciences, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company’s platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects that induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in cancer patients.
Receive News & Ratings for ARMO Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARMO Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.